Stereotactic ablative body radiotherapy (SABR) has a role as definitive therapy in many tumor sites; however, its role in the treatment of breast cancer is less well explored. Currently, SABR has been investigated in the neoadjuvant and adjuvant setting with a number of ongoing feasibility studies. However, its use comes with a number of radiobiological and technical challenges that require further evaluation. We have learned much from other extracranial disease sites such as lung, brain, and spine, where definitive treatment with SABR has shown encouraging outcomes. In women with breast cancer, SABR may eliminate the need for invasive surgery, reducing healthcare costs and hospital stays and providing an additional curative option for early-stage disease. This poses the following question: Is there a role for SABR as a definitive therapy in breast cancer?
Barry, A., & Fyles, A. (2018). Establishing the role of stereotactic ablative body radiotherapy in early-stage breast cancer. International Journal of Breast Cancer. Hindawi Limited. https://doi.org/10.1155/2018/2734820